Corrigendum to Ipilimumab-induced hypophysitis in melanoma patients: An Australian case series. [Intern Med J (2015), 45, 1066-1073]. DOI: 10.1111/imj.12819;Ipilimumab-induced hypophysitis in melanoma patients: An Australian case series

Internal Medicine Journal

Volumn 45, Issue 10, 2015, Pages 1066-1073

  Lam, T ^a   Chan, M M K ^a,b,c   Sweeting, A N ^b,d   De Sousa, S M C ^e   Clements, A ^a,b   Carlino, M S ^a,b,f   Long, G V ^b,f   Tonks, K ^e,g   Chua, E ^b,d   Kefford, R F ^a,b,f,h   Chipps, D R ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f MELANOMA INSTITUTE AUSTRALIA   (Australia)

^g MACQUARIE UNIVERSITY   (Australia)

^h GOSFORD HOSPITAL   (Australia)

Author keywords

Hypophysitis; Hypopituitarism; Immune related adverse event; Immunotherapy; Ipilimumab; Melanoma

Indexed keywords

ANTIBODY; DACARBAZINE; GLUCOCORTICOID; HYDROCORTISONE; IPILIMUMAB; LEVOTHYROXINE; NY ESO 1 ANTIGEN; PEMBROLIZUMAB; PREDNISONE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; AUSTRALIAN; CASE STUDY; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOPHYSIS ADRENAL SYSTEM; HYPOPHYSIS THYROID SYSTEM; HYPOPHYSITIS; HYPOTHYROIDISM; MALE; MELANOMA; PRIORITY JOURNAL; AUSTRALIA; CHEMICALLY INDUCED; CLINICAL TRIAL; HORMONE SUBSTITUTION; HYPOPITUITARISM; IMMUNOLOGY; IMMUNOTHERAPY; MIDDLE AGED; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; SKIN NEOPLASMS;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AUSTRALIA; CTLA-4 ANTIGEN; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOPITUITARISM; IMMUNOTHERAPY; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS;

EID: 84942913084     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12943     Document Type: Erratum

References (23)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB etal. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
2. United States Department of Health and Human Services. National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 NCI, NIH, DHHS. 2009, NIH publication # 09-7473.
3. Weber JS, Dummer R, de Pril V, Lebbe C, Hodi FS. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013; 119: 1675-1682.
4. Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A etal. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 2014; 99: 4078-4085.
5. Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE etal. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006; 29: 455-463.
6. Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014; 21: 371-381.
7. Alexander M, Mellor JD, McArthur G, Kee D. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma. Med J Aust 2014; 201: 49-53.
8. De Sousa SM, Long GV, Tonks KT. Ipilimumab-induced hypophysitis: early Australian experience. Med J Aust 2014; 201: 198-199.
9. Bristol-Myers Squibb. Yervoy (ipilimumab): immune-mediated adverse reaction management guide. 2011 [cited 2015 Feb 21]. Available from URL: http://www.hcp.yervoy.com/pdf/rems-management-guide.pdf
10. Torino F, Barnabei A, Paragliola RM, Marchetti P, Salvatori R, Corsello SM. Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol 2013; 169: R153-164.
11. Juszczak A, Gupta A, Karavitaki N, Middleton MR, Grossman AB. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol 2012; 167: 1-5.
12. Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010; 13: 29-38.
13. Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US etal. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005; 28: 593-598.
14. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE etal. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13: 6681-6688.
15. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A etal. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008; 105: 3005-3010.
16. Vaidya B, Pearce S. The emerging role of the CTLA-4 gene in autoimmune endocrinopathies. Eur J Endocrinol 2004; 150: 619-626.
17. Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 2014; 6: 230ra45.
18. Vita R, Guarneri F, Agah R, Benvenga S. Autoimmune thyroid disease elicited by NY-ESO-1 vaccination. Thyroid 2014; 24: 390-394.
19. Min L, Vaidya A, Becker C. Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. Endocr Pract 2012; 18: 351-355.
20. Torino F, Barnabei A, De Vecchis L, Salvatori R, Corsello SM. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist 2012; 17: 525-535.
21. Carpenter KJ, Murtagh RD, Lilienfeld H, Weber J, Murtagh FR. Ipilimumab-induced hypophysitis: MR imaging findings. AJNR Am J Neuroradiol 2009; 30: 1751-1753.
22. Thodou E, Asa SL, Kontogeorgos G, Kovacs K, Horvath E, Ezzat S. Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings. J Clin Endocrinol Metab 1995; 80: 2302-2311.
23. Lammert A, Schneider HJ, Bergmann T, Benck U, Krämer BK, Gärtner R etal. Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy. Exp Clin Endocrinol Diabetes 2013; 121: 581-587.